HIF1A and acute kidney injury: A deeper understanding of AKI pathogenesis will facilitate the development of drugs that precisely target HIF-1α (e.g., small-molecule inhibitors or activators) to correct its aberrant activity, thereby ameliorating inflammatory responses, cellular metabolic imbalances, and apoptotic processes.